Multifocal motor neuropathy

Current Opinion in Neurology

Volumn 18, Issue 5, 2005, Pages 567-573

  Léger, Jean Marc ^a   Behin, Anthony ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anti GM1 antibodies; Chronic immune mediated polyneuropathies; Conduction blocks; Intravenous immunoglobulins; Multifocal acquired motor neuropathy; Multifocal motor neuropathy

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANGLIOSIDE GM1; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMYLASE BLOOD LEVEL; ANOREXIA; AUTOIMMUNITY; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ELECTROPHYSIOLOGY; FILTRATION; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; MAINTENANCE DRUG DOSE; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; NERVE BIOPSY; NERVE BLOCK; NERVE DEGENERATION; NERVE FIBER DEGENERATION; PLASMAPHERESIS; POLYRADICULONEUROPATHY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 26944484408     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000175937.31569.15     Document Type: Review

References (60)

1. Roth G, Roth J, Magistris M, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block. Eur Neurol 1986; 25:416-423.
2. Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology 1986; 36:1260-1263.
3. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988; 11:103-107.
4. Pestronk A, Comblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24:73-78.
5. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001; 115:4-18.
6. Léger JM. Multifocal motor neuropathy with persistent conduction blocks. Rev Neurol 2004; 160:889-898.
7. Workshop report. 79th ENMC International Workshop: Multifocal motor neuropathy 14-15 April 2000 Hilversum, The Netherlands. Muscle Nerve 2001; 11:309-314.
8. Olney RK, Lewis RA, Putnam TD, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003; 27:117-121.
9. Pestronk A, Chaudhry V, Feldman EL, et al. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titres of antiglycolipid antibodies. Ann Neurol 1990; 27:316-326.
10. Willison HJ, Veitch J, Swan AV, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999; 6:71-77.
11. Willison HJ, Yuki NM. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125:2591-2625.
12. Léger JM. Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 1995; 8:359-363.
13. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24:311-324.
14. Kieseier BC, Kieffer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30:131-156. This is an excellent review on the pathophysiology, diagnostic criteria, therapy and management of the so-called dysimmune polyneuropathies including Guillain-Barré syndrome, CIDP and MMN.
15. van Doom PA, Garssen MPJ. Treatment of immune neuropathies. Curr Opin Neurol 2002; 15:623-631.
16. Bouche P, Moulonguet A, Ben Younes-Chennoufi A, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995; 59:38-44.
17. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999; 22:560-566.
18. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32:958-964.
19. Viala K, Renié T, Maisonobe T, et al. Follow-up and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127:2010-2017. Although not contributing to the specific objective of this review, this most important retrospective series of patients with LSS is of particular interest in distinguishing two different patterns according to the natural history of the disease, and pointing out different responses to treatment with corticosteroids/IVIg infusions from those observed in classic CIDP.
20. Verschueren A, Azulay JP, Attarian S, et al. Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve 2005; 31:88-94. This retrospective study nicely underlines the differences between MMN and MADSAM neuropathy from the charts of two large cohorts of patients.
21. Pestronk A, Lopate G, Komberg AJ, et al. Distal lower motor neuron syndrome with high titer serum anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1994; 44:2027-2031.
22. Katz JS, Barohn RJ, Kojan S, et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology 2002; 58:615-620.
23. Fischer D, Grothe C, Schmidt S, Schröder R. On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy. J Neurol 2004; 251:1204-1207. A new and interesting description of six patients with MAMA, underlining the interest of looking for neurogenic patterns in paraspinal muscles and performing dosage of anti-GDI a antibodies.
24. Corse AM, Chaudhry W, Crawford TO, et al. Sural nerve pathology in multifocal motor neuropathy. Ann Neurol 1996; 39:319-325.
25. Oh SJ, Claussen GC, Odabasi Z, Palmer CP. Multifocal demyelinating motor neuropathy: pathological evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology 1995; 45:1828-1832.
26. Kaji R, Oka N, Tsuji T, et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993; 33:152-158.
27. Taylor BV, Dyk PJB, Engelstad J, et al. Multifocal motor neuropathy: pathological alterations at the site of conduction block. J Neuropathol Exp Neurol 2004; 63:129-137. One of the rare pathological studies conducted in the proximal segments of affected nerves in MMN.
28. Cai Z, Blumbergs PC, Koblar SA, et al. Peripheral nervous system and central nervous system pathology in rapidly progressive lower motor neuron syndrome with immunoglobulin M anti-GM1 ganglioside antibody. J Peripher Nerv Syst 2004; 9:79-91.
29. Merkies ISJ, Schmitz PIM, Samjin JPA, et al. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000; 23:1393-1401.
30. Hughes R, CIDP and MMN trial group. 129th ENMC International Workshop: Clinical Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy, 27th October 2004. Schiphol Airport, The Netherlands. Neuromusc Disord 2005; 15:321-325. The recent conclusions of a group of experts in conducting future trials on CIDP and MMN.
31. Merkies IS, Schmitz PI, van der Méché FG, et al. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002; 72:596-601.
32. Merkies IS, Schmitz PI, van der Méché FG, van Doom PA. Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve 2003; 28:93-100.
33. Hughes RAC, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2001; 50:195-201.
34. Holman R, Lindeboom R, Vermeulen M, de Haan RJ. AMC Linear Disability Score project in a population requiring residential care: psychometric properties. Health Qual Life Outcomes 2004; 2:42.
35. Czaplinski A, Steck AJ. Immune mediated neuropathies: an update on therapeutic strategies. J Neurol 2004; 251:127-137. Careful overview of therapeutic options in chronic dysimmune neuropathies.
36. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291:2367-2375. Good review of current results with IVIg therapy in autoimmune neuromuscular diseases, including MMN.
37. van Schaik IN, Vermeulen MM, de Haan R, van den Berg LH. Intravenous immunoglobulin for multifocal motor neuropathy [Cochrane review]. Cochrane Database Syst Rev 2004; (3):CD004429. Cochrane review concluding that there is evidence for use of IVIg as first-line treatment in MMN.
38. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressive treatments for multifocal motor neuropathy [Cochrane review]. Cochrane Database Syst Rev 2002; (2):CD003217.
39. van den Berg LH, Lockhorst H, Wokke JHJ. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology 1997; 48:1135.
40. Carpo M, Capellari A, Mora G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998; 50:1480-1482.
41. Nobile-Orazio E, Capellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002; 6:761-766.
42. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44:429-432.
43. van den Berg LH, Kerkhoff H, Oey OI, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995; 59:248-252.
44. Federico P, Zochdone DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55:1256-1262.
45. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124:145-153.
46. van den Berg-Vos RM, Franssen H, Wokke HJ, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000; 41:919-926.
47. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000; 23:900-908.
48. Elliot JL, Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin. Neurology 1994; 44:967-968.
49. van den Berg-Vos RM, Franssen H, Wokke JHJ, van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002; 125:1875-1886.
50. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in M multifocal motor neuropathy? Neurology 2004; 62:666-668. Careful retrospective study of 10 patients with MMN treated in long-term therapy with IVIg infusions, showing a slightly progressive motor deterioration associated with axonal loss.
51. Vucic S, Black KR, Tick Chong PS, Gros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004; 63:1264-1269. Careful retrospective study of 10 patients with MMN, showing that monthly therapy with IVIg infusions prevents motor deterioration and improves both reinnervation and conduction blocks.
52. Léger JM, Viala K, Cancalon F, et al. Are intravenous immunoglobulins a long-term therapy of multifocal motor neuropathy? A retrospective study of response to IVIg and of its predictive criteria in 40 patients [abstract]. Neurology 2005; 64 (Suppl 1):A412.
53. Hausmanowa-Petrusewicz I, Rowinska-Marcinska K, Kopek K. Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand 1991; 84:40-45.
54. Umapathi T, Hughes RAC. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2003; 2:683-685.
55. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352:1343-1356.
56. Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004; 29:748-749. A letter to the Editor outlining the possible interest of mycophenolate mofetil in reducing IVIg infusions in MMN.
57. Van den Berg-Vos RM, van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon beta 1a. Neurology 2000; 54:1518-1521.
58. Nemni R, Santuccio G, Calabrese E, et al. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol 2003; 250:1118-1120.
59. Rojas-Garcia R, Gallardo E, de Andres I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 2004; 61:1814-1816.
60. Rüegg SJ, Fuhr P, Steck A. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004; 63:2178-2179.